Oncolytics Biotech Inc T.ONC

Immunology wars: Tumor Microenvironment - simply xplained

[Noteable]

https://youtu.be/85qfMcj9m9g?feature=shared

[Noteable]

Activation of innate immune system and expression of pattern recognition receptors (PRRs) and antigen presentation markers were observed under reovirus and anti-PD-1 treatment that additionally reduced immunosuppressive macrophages. This led to an increase in T cell subsets, increase in effector T cell activation, and decrease in exhaustion markers specifically within CT26

[Noteable]

In recent years, a new class of immunotherapies that target immune cells within the tumor microenvironment has transformed the treatment of certain types of cancer. Leading this revolution are the so-called immune checkpoint inhibitors that reinvigorate specialized immune cells – called T cells – to recognize, attack and destroy cancer cells.  “These therapies can release the brake that

[Noteable]

The tumor microenvironment plays a critical role in cancer progression and resistance to treatment.   The tumor microenvironment (TME) is one of the most formidable obstacles in the fight against cancer since it creates an immune-suppressive barrier which shields tumors from immune system attacks. The ability of transforming the TME from a cancer-supportive to cancer-hostile